Printer Friendly

CALIFORNIA BIOTECHNOLOGY NAMES DR. ELLIOTT GROSSBARD TO VICE PRESIDENT OF MEDICAL AND REGULATORY AFFAIRS

 CALIFORNIA BIOTECHNOLOGY NAMES DR. ELLIOTT GROSSBARD TO
 VICE PRESIDENT OF MEDICAL AND REGULATORY AFFAIRS
 MOUNTAIN VIEW, Calif., Dec. 3 /PRNewswire/ -- California Biotechnology Inc. (NASDAQ: CBIO) today announced that it has named Elliott B. Grossbard, M.D., as Vice President of Medical and Regulatory Affairs. Dr. Grossbard joins Cal Bio with extensive clinical development expertise gained in the biotechnology industry, including eight years with Genentech Inc. Dr. Grossbard was the architect of the successful clinical development strategy for Genentech's clot dissolving drug, tissue plasminogen activator (t-PA), and he directed the clinical program that resulted in the product's approval by the Food and Drug Administration.
 "The appointment of Dr. Grossbard represents a key step in building our capabilities in pharmaceutical development," commented Richard L. Casey, Cal Bio president and CEO. "With Auriculin(R) atrial natriuretic peptide and fibroblast growth factor (FGF) advancing toward Phase III testing, he will play a major role in guiding our products through the final stages of clinical development and the regulatory approval process." A third product, insulinotropin, is licensed to Pfizer Inc. and undergoing Phase II evaluation as a treatment for Type II diabetes.
 "Dr. Grossbard brings to Cal Bio broad expertise in managing the clinical development of biopharmaceutical products," Casey continued. "We are pleased to welcome him as a member of Cal Bio's senior management team."
 Dr. Grossbard, 43, joins Cal Bio from HemaGen/PFC where he was Vice President, Medical Affairs. From 1982 to 1990, Dr. Grossbard held a number of positions at Genentech most recently as Director, Clinical Research. Dr. Grossbard, a board certified internist and hematologist, received an M.D. from Columbia University in 1973 and a B.A. from Columbia College in 1969. He also holds a Master of Studies in Law from the Yale University School of Law.
 California Biotechnology Inc. is a biotechnology company engaged in the discovery, development and commercialization of novel human therapeutics. Cal Bio focuses its efforts in three areas -- cardiopulmonary disease, tissue repair, and metabolic disorders. The company develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical companies.
 -0- 12/3/91
 /CONTACT: Virginia Walker of Cal Bio, 415-940-6631 or 415-966-1550, or Robert Gottlieb of Feinstein Partners Inc., 617-577-8110/
 (CBIO) CO: California Biotechnology Inc. ST: California IN: MTC SU: PER


DG -- SJ001 -- 8741 12/03/91 12:01 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:388
Previous Article:CALIFORNIA BIOTECHNOLOGY NAMES DR. KENNETH LUSKEY TO DIRECTOR OF DIABETES AND OBESITY
Next Article:UNITED AMERICAN HEALTHCARE CORPORATION REPORTS ON ANNUAL MEETING
Topics:


Related Articles
CALGENE ANNOUNCES FIVE PROMOTIONS; TWO NEW OFFICERS NAMED
RGENE THERAPEUTICS HIRES MARY TREUHAFT, PH.D. AS VICE PRESIDENT OF REGULATORY AFFAIRS
Nautilus Biotech Announced Today The Appointment of Reinhard Koenig, MD, To Its Management Team.
Kevin Swiss, PhD, Joins PharmaNet as Associate Director, Regulatory Consulting.
BioVest International Announces Expansion Of Board Of Directors; BioVest Expands Board from 7 to 11 Directors.
Peptimmune Announces Two Additions to Management Team.
OncoGenex Hires Senior Executives and Establishes U.S. Based Clinical and Regulatory Operations.
Rigel to Host Investor Briefing on December 15, 2005.
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters